Ryanodex is a skeletal muscle relaxant indicated for the treatment of malignant hyperthermia in conjunction with appropriate supportive measures in patients with a high risk.

Insight:

Dosing: Administer by intravenous push at a minimum of 1 mg/kg.

Dosage forms: For injectable suspension 250 mg of lyophilized powder in a single-dose vial for reconstitution.

Adverse events: Administration to conscious subjects is associated with loss of grip strength and weakness in the legs, drowsiness, and dizziness.

Mechanism of action: The addition of dantrolene to the triggered malignant hyperthermic muscle cell may reestablish a normal level of ionized calcium in the myoplasm.

Manufacturer: Eagle Pharmaceuticals

Source

Approval [Rx ONLY] (ryanodex.com)